Physicians' Academy for Cardiovascular Education

Asian Interchange on Diabetes

This Asian Interchange on Diabetes is in collaboration with PACE-CME and ACROSS T2D (Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes). During this Asian Interchange on Diabetes participants will receive a balanced review on how novel developments might impact their clinical practice in managing patients with T2DM.

CV Protection in the EMPA-REG OUTCOME Trial: A ‘Thrifty Substrate’ Hypothesis

Lecture - July 31, 2016 - Asian Interchange on Diabetes meeting - Michael Mark, MD, Boehringer Ingelheim – Cardiometabolic Diseases Research

Update on DPP4 inhibition in T2DM: Implications from recent and ongoing trials

Lecture - July 31, 2016 - Asian Interchange on Diabetes meeting - Richard E. Pratley, MD – Florida Hospital Diabetes Institute, Orlando, Fl, USA

Understanding Diabetic Kidney Disease: What are the best options for clinical management?

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Per-Henrik Groop, MD – University of Helsinki, Helsinki, Finland

Diabetes and Cardiovascular Disease: A review of new outcome data impacting practice

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - David Fitchett, MD – University of Toronto, Canada

Need for ongoing clinical innovation in management of T2DM: A closer look at the development process of new entities

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Michael Mark, MD, Boehringer Ingelheim – Cardiometabolic Diseases Research

Management of hyperglycemia in type 2 diabetes: Update on novel trends and developments

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Richard E. Pratley, MD – Florida Hospital Diabetes Institute, Orlando, FL, USA

Diabetes in Asia: What is different from the west?

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Chaicharn Deerochanawong, MD – Rajavithi Hospital College of Medicine, Bangkok, Thailand
##SCROLLER_ITEMS_FULL_TITLE##

The effect of treatment with DPP-4 inhibition on renal complications in diabetic patients.

3' education - Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)
##SCROLLER_ITEMS_FULL_TITLE##

A changing treatment paradigm in diabetes

3' education - July 30, 2016 - Bangkok, Thailand - Richard E. Pratley, MD (Florida Hospital Diabetes Institute, Orlando, FL, USA)

SGLT2 inhibition in diabetic kidney disease

3' education - Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)

Diabetes and Cardiovascular Disease: A review of new outcome data impacting practice

Lecture - July 30, 2016 - Asian Interchange on Diabetes, Bangkok - David Fitchett, MD - University of Toronto, Canada

The effect of treatment with DPP-4 inhibition on renal complications in diabetic patients.

3' education - Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)
##OVERVIEW_ITEMS_KEY_PHRASE##

Good glycaemic control can now be achieved with a lower risk of hypoglycaemia than before. Prof. Groop elaborates on the evidence on whether improving glycaemic control with DPP-4 inhibitors translates into a reduction of renal complications.

A changing treatment paradigm in diabetes

3' education - July 30, 2016 - Bangkok, Thailand - Richard E. Pratley, MD (Florida Hospital Diabetes Institute, Orlando, FL, USA)
##OVERVIEW_ITEMS_KEY_PHRASE##

Recent outcome studies have shown evidence for a CV benefit with novel antidiabetic therapies such as DPP4 inhibitors and SGLT2 inhibitors. Dr. Pratley summarises the observations and speculates on how these findings may affect treatment of patients with diabetes in the near future.

SGLT2 inhibition in diabetic kidney disease

3' education - Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)

Very recently, data became available of use of the SGLT2-inhibitor empagliflozin in patients with diabetic kidney disease, a condition associated with increased risk of CV complications. Prof. Groop shares the data that suggest that empagliflozin can reduce or prevent the onset of this condition.

Diabetes in Asia: What is different from the west?

Slides (presentation) - Aug. 21, 2016 - Asian Interchange on Diabetes meeting - Chaicharn Deerochanawong MD, FRCP(T)

Presentation prepared and held by Chaicharn Deerochanawong MD, Chulalongkorn University, Bangkok, Thailand at the Asian Interchange on Diabetes meeting held on July 30-31, 2016 in Bangkok, Thailand

Management of hyperglycemia in type 2 diabetes: Update on novel trends and developments

Slides (presentation) - July 30, 2016 - Asian Interchange on Diabetes meeting - Richard E. Pratley, MD

Presentation prepared and held by Richard E. Pratley, MD, Florida Hospital Diabetes Institute, Orlando, Fl, USA at the Asian Interchange on Diabetes meeting held on July 30-31, 2016 in Bangkok, Thailand